Terms: = Germ cell tumor AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Diagnosis
250 results:
1. tumor-infiltrating macrophage associated lncRNA signature in cutaneous melanoma: implications for diagnosis, prognosis, and immunotherapy.
Wan Q; Deng Y; Wei R; Ma K; Tang J; Deng YP
Aging (Albany NY); 2024 Mar; 16(5):4518-4540. PubMed ID: 38475660
[TBL] [Abstract] [Full Text] [Related]
2. Concentrations of S100B and neurofilament light chain in blood as biomarkers for checkpoint inhibitor-induced CNS inflammation.
Bjursten S; Zhao Z; Al Remawi H; Studahl M; Pandita A; Simrén J; Zetterberg H; Lundell AC; Rudin A; Ny L; Levin M
EBioMedicine; 2024 Feb; 100():104955. PubMed ID: 38171113
[TBL] [Abstract] [Full Text] [Related]
3. Analysis of Histomorphologic/Molecular Association and Immune Checkpoint Regulators in Epithelioid Glioblastoma and Pleomorphic Xanthoastrocytoma: Are These tumors Potential Candidates for Immune Checkpoint Blockade?
Mahajan S; Singh J; Dandapath I; Jha P; Chaturvedi S; Ahuja A; Bhardwaj M; Saran R; Garg A; Sharma MC; Manjunath N; Suri A; Sarkar C; Suri V
Appl Immunohistochem Mol Morphol; 2024 Feb; 32(2):84-95. PubMed ID: 38158760
[TBL] [Abstract] [Full Text] [Related]
4. Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015-2018 in Greece. The 'SUMMER' study: a retrospective multicenter chart review project.
Bafaloukos D; Kouzis P; Gouveris P; Boukovinas I; Kalbakis K; Baka S; Kyriakakis G; Moschou D; Molfeta A; Demiri S; Mavroudis D; Spanoudi F; Dimitriadis I; Gogas H
Melanoma Res; 2024 Apr; 34(2):152-165. PubMed ID: 38092014
[TBL] [Abstract] [Full Text] [Related]
5. Liquid Biopsy in Low-Grade Glioma: A Systematic Review and a Proposal for a Clinical Utility Score.
Zanin L; Sachkova A; Panciani PP; Rohde V; Fontanella MM; Schatlo B
Cell Mol Neurobiol; 2023 Nov; 43(8):3833-3845. PubMed ID: 37704931
[TBL] [Abstract] [Full Text] [Related]
6. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).
Ascierto PA; Agarwala SS; Warner AB; Ernstoff MS; Fox BA; Gajewski TF; Galon J; Garbe C; Gastman BR; Gershenwald JE; Kalinski P; Krogsgaard M; Leidner RS; Lo RS; Menzies AM; Michielin O; Poulikakos PI; Weber JS; Caracò C; Osman I; Puzanov I; Thurin M
J Transl Med; 2023 Jul; 21(1):508. PubMed ID: 37507765
[TBL] [Abstract] [Full Text] [Related]
7. Machine learning algorithm to predict response to immunotherapy in real-life settings for patients with advanced melanoma.
Frenard C; Blanchet K; Lecerf P; Varey E; Khammari A; Dréno B
Eur J Dermatol; 2023 Apr; 33(2):75-80. PubMed ID: 37431109
[TBL] [Abstract] [Full Text] [Related]
8. Overcoming the immune suppressive nature of glioblastoma by leveraging the surgical intervention - current status and future perspectives.
Duerinck J; Tuyaerts S; Movahedi K; Neyns B
Front Immunol; 2023; 14():1183641. PubMed ID: 37275902
[TBL] [Abstract] [Full Text] [Related]
9. Analysis of characteristics of four patients with adrenal unicentric Castleman disease.
Yu H; Wang Y; Li Y; Du J; Guo Q; Gu W; Lyu Z; Dou J; Mu Y; Zang L
Front Endocrinol (Lausanne); 2023; 14():1181929. PubMed ID: 37265694
[TBL] [Abstract] [Full Text] [Related]
10. Changes of peripheral T cell subsets in melanoma patients with immune-related adverse events.
Müller B; Bärenwaldt A; Herzig P; Zippelius A; Maul LV; Hess V; König D; Läubli H
Front Immunol; 2023; 14():1125111. PubMed ID: 37122748
[TBL] [Abstract] [Full Text] [Related]
11. Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG.
Franklin C; Mohr P; Bluhm L; Meier F; Garzarolli M; Weichenthal M; Kähler K; Grimmelmann I; Gutzmer R; Utikal J; Terheyden P; Herbst R; Haferkamp S; Pfoehler C; Forschner A; Leiter U; Ziller F; Meiss F; Ulrich J; Kreuter A; Gebhardt C; Welzel J; Schilling B; Kaatz M; Scharfetter-Kochanek K; Dippel E; Nashan D; Sachse M; Weishaupt C; Löffler H; Gambichler T; Loquai C; Heinzerling L; Grabbe S; Debus D; Schley G; Hassel JC; Weyandt G; Trommer M; Lodde G; Placke JM; Zimmer L; Livingstone E; Becker JC; Horn S; Schadendorf D; Ugurel S
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37028819
[TBL] [Abstract] [Full Text] [Related]
12. Polyoxometalate-cyclodextrin supramolecular entities for real-time in situ monitoring of dopamine released from neuroblastoma cells.
Shetty SS; Moosa B; Zhang L; Alshankiti B; Baslyman W; Mani V; Khashab NM; Salama KN
Biosens Bioelectron; 2023 Jun; 229():115240. PubMed ID: 36963326
[TBL] [Abstract] [Full Text] [Related]
13. Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations.
Park BC; Narayanan S; Gavraldis A; Ye F; Fan R; Sullivan RJ; Boland G; Reynolds KL; Balko JM; Carlino MS; Long GV; Zubiri L; Menzies AM; Johnson DB
Oncoimmunology; 2023; 12(1):2188719. PubMed ID: 36926262
[TBL] [Abstract] [Full Text] [Related]
14. Iris melanoma outcomes based on the Cancer Genome Atlas (TCGA) classification in 78 consecutive patients.
Cherkas E; Negretti GS; Zeiger JS; Shields CL
Ophthalmic Genet; 2022 Dec; 43(6):736-741. PubMed ID: 36326016
[TBL] [Abstract] [Full Text] [Related]
15. Malignant gastrointestinal neuroectodermal tumor: A case-based review of literature.
Mishra P; Biswas D; Pattnaik SA; Patra S; Muduly DK; Balasubiramaniyan V; Adhya AK
J Cancer Res Ther; 2022; 18(4):885-897. PubMed ID: 36149136
[TBL] [Abstract] [Full Text] [Related]
16. Usefulness of intraoperative rapid immunohistochemistry in the surgical treatment of brain tumors.
Inoue A; Watanabe H; Kondo T; Katayama E; Miyazaki Y; Suehiro S; Yamashita D; Taniwaki M; Kurata M; Shigekawa S; Kitazawa R; Kunieda T
Neuropathology; 2023 Jun; 43(3):209-220. PubMed ID: 36128673
[TBL] [Abstract] [Full Text] [Related]
17. Combination of serum 5-S-cysteinyldopa, melanoma inhibitory activity and IL-8 improves the diagnostic accuracy of malignant melanoma compared with individual markers.
Katoh Y; Hara H; Harada T; Hirai S
Medicine (Baltimore); 2022 Sep; 101(35):e30471. PubMed ID: 36107519
[TBL] [Abstract] [Full Text] [Related]
18. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).
Ascierto PA; Agarwala SS; Blank C; Caracò C; Carvajal RD; Ernstoff MS; Ferrone S; Fox BA; Gajewski TF; Garbe C; Grob JJ; Hamid O; Krogsgaard M; Lo RS; Lund AW; Madonna G; Michielin O; Neyns B; Osman I; Peters S; Poulikakos PI; Quezada SA; Reinfeld B; Zitvogel L; Puzanov I; Thurin M
J Transl Med; 2022 Sep; 20(1):391. PubMed ID: 36058945
[TBL] [Abstract] [Full Text] [Related]
19. Haemophagocytic lymphohistiocytosis as a complication of combination anti-PD-1 and anti-ctla-4 checkpoint inhibitor immunotherapy for metastatic melanoma, and the outcome of rechallenge with single-agent anti-PD-1 immunotherapy.
Holmes Z; Courtney A; Hiong A
BMJ Case Rep; 2022 Aug; 15(8):. PubMed ID: 35948362
[TBL] [Abstract] [Full Text] [Related]
20. Metastatic malignant melanoma of the breast: report of a case and review of the literature.
Mastoraki A; Gkiala A; Theodoroleas G; Mouchtouri E; Strimpakos A; Papagiannopoulou D; Schizas D
Folia Med (Plovdiv); 2022 Apr; 64(2):354-358. PubMed ID: 35851793
[TBL] [Abstract] [Full Text] [Related]
[Next]
